宣肺止嗽合剂治疗小儿支气管炎有效性与安全性的系统评价  

Systematic review and Meta-analysis of efficacy and safety of Xuanfei Zhisou Mixture in treatment of bronchitis in children

作　　者：常文婧 李云[1] 张煦东 宋月红 陈薇[1] CHANG Wen-jing;LI Yun;ZHANG Xu-dong(Center for Evidence-based Medicine,Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]北京中医药大学循证医学中心,北京100029 [2]甘肃普安制药股份有限公司,甘肃武威733006

出　　处：《中国处方药》2023年第12期18-22,共5页Journal of China Prescription Drug

摘　　要：目的系统评价宣肺止嗽合剂治疗小儿支气管炎的有效性和安全性。方法系统检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献系统(SinoMed)、PubMed、EMbase和Cochrane Library数据库,检索时限为建库至2022年6月。纳入应用宣肺止嗽合剂治疗小儿支气管炎的随机对照试验,采用Cochrane风险评估工具ROB 2.0对纳入研究进行方法学质量评价,并应用RevMan 5.4软件进行数据统计分析。结果共纳入7项随机对照试验,共计771例患儿,年龄范围0~14岁,纳入研究总体方法学质量不高。结果显示宣肺止嗽合剂联合常规抗感染及对症治疗可以提高支气管炎患儿临床疗效总有效率,缩短咳嗽消失时间和肺部啰音消失时间;宣肺止嗽合剂联合重组人干扰素可提高治疗总有效率,缩短咳嗽消失时间、喘息缓解时间和肺部啰音消失时间,改善呼吸功能等。宣肺止嗽合剂对比氨溴特罗口服液可缩短支气管炎患儿退热时间、咳嗽消失时间以及肺部啰音消失时间。未发生明显不良事件。结论宣肺止嗽合剂在改善支气管炎患儿发热、咳嗽、肺部啰音等症状方面较西医常规治疗具有潜在优势,且比较安全,但纳入研究的方法学质量较差、样本量较小、研究数目较少,所获结论可靠性较低,未来仍需开展更高质量的临床试验验证。Objective This study systematically evaluated the effectiveness and safety of Xuanfei Zhisou Mixture in the treatment of bronchitis in children.Methods The databases including CNKI,Wanfang,VIP,SinoMed,PubMed,EMbase and Cochrane Library were systematically searched for randomized controlled trial(RCT)of Xuanfei Zhisou Mixture in the treatment of bronchitis in children reported from database inception to June 2022.The methodological quality of the included RCTs was evaluated via the Cochrane risk of bias tool ROB2.0 and meta-analysis was performed using RevMan 5.4 statistical software.Results A total of 7 RCTs with 771 children aged 0~14 years were included.The overall methodological quality of the included studies was not high.The meta-analysis results showed that Xuanfei Zhisou Mixture combined with conventional therapy(anti-infective and symptomatic therapy)can improve the total effective ratio(clinical effectiveness)and shorten the duration time of cough and pulmonary rales in children with bronchitis.Xuanfei Zhisou Mixture combined with recombinant human interferon can not only improve the total effective rate,but also shorten the duration time of cough,wheezing and pulmonary rales.Conclusion The Xuanfei Zhisou Mixture can shorten the duration of fever,cough and pulmonary rales more than ambroterol oral liquid.There were no significant adverse events in 4 studies and other studies were not reported.In conclusion,Xuanfei Zhisou Mixture has potential advantages in improving the symptoms of fever,cough,pulmonary rales in children with bronchitis compared with conventional western medicine therapy.However,in view of the limited number of included studies,small sample size and low methodological quality,the results of this study need to be confirmed with high-level clinical trials.

关 键 词：宣肺止嗽合剂 小儿支气管炎 系统评价 META分析 

分 类 号：R725.6[医药卫生—儿科]